Arbutus Biopharma (ABUS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on the stock ...
Arbutus Biopharma (NASDAQ:ABUS) announced on Monday its 2025 corporate objectives and provided a financial update. The company had cash, cash equivalents and investments in marketable securities ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback